Finding Mentors and Forging Connections in the Brain Cancer Field

Commentary
Video

The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.

Yoshie Umemura, MD, spoke with CancerNetwork® about advice she would offer to aspiring neuro-oncologists who aim to progress in the brain cancer field. Specifically, she focused on what to look out for in terms of mentorship.

Above all else, Umemura, the chief medical officer of the Ivy Brain Tumor Center, division chief of Neuro-Oncology, and the William and Joan Shapiro chair of Neuro-Oncology at Barrow Neurological Institute, emphasized having the confidence to ask others outside of one’s institution to form new connections and mentorships. Additionally, she described how those in the field can pay it forward by being open to mentoring other aspiring neuro-oncologists.

Transcript:

I have spoken with some people who felt they lacked a mentor. The common things I hear are, “Oh, there wasn’t anyone like that at my institution.” The best advice I can give them is to just ask. When you are at a conference and you meet someone, you think you might click with, you’re intrigued about, or you’re impressed with, you can shoot an email and ask them if they would be open to chatting with you about a question or mentoring you. I have multiple mentors outside of my institution, and I have been very fortunate to have them. At the same time, I’ve asked [them]. The worst thing that’s going to happen is they [may be] too busy, right? No one is going to make you feel terrible about yourself just because you showed an initiative to get a mentor. [You should also] pay it forward. Always be open to mentoring others; that’s the only way to move forward. Don’t limit yourself to just what’s around you. It [speaks] to the collaborative aspect and how to operate as an outsider. You’re not an outsider as long as you make the connection; you can just wedge yourself in. Just ask.

Recent Videos
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.